Skip to main content

Table 2 Patient characteristics at baseline (ITT population)

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

 Arm A (Cap+Bev / Eve+Exe) (N = 39)Arm B (Eve+Exe / Cap+Bev) (N = 38)
Age [years], median (range)64.4 (47.0–83.6)65.9 (49.8–86.0)
Ethnicity, n (%)
 Caucasian38 (97.4%)37 (97.4%)
 Asian1 (2.6%)1 (2.6%)
BMI [kg/m2], median (quartiles)25.6 (22.5–28.4)24.9 (22.7–31.1)
ECOG Performance Status, n (%)
 019 (48.7%)17 (44.7%)
 119 (48.7%)20 (52.6%)
 21 (2.6%)1 (2.6%)
Menopausal status, n (%)
 Postmenopausal39 (100%)38 (100%)
Concomitant diseases, n (%)
 Yes33 (84.6%)35 (92.1%)
 No6 (15.4%)3 (7.9%)
Visceral disease or local relapse, n (%)27 (69.2%)26 (68.4%)
Non-visceral disease, n (%)12 (30.8%)12 (31.6%)
Metastatic sitesa, n (%)
 Bone28 (71.8%)29 (76.3%)
 Liver15 (38.5%)16 (42.1%)
 Lung8 (20.5%)10 (26.3%)
Histology of tumor, n (%)
 Invasive ductal27 (69.2%)24 (63.2%)
 Invasive lobular7 (17.9%)12 (31.6%)
 Inflammatory cancer1 (2.6%)0
 Not otherwise specified4 (10.3%)2 (5.3%)
DFIb [years], median (quartiles)4.7 (1.4–10.9)5.0 (1.3–8.2)
Time since initial diagnosis [years], median (quartiles)9.6 (3.6–13.0)6.6 (2.5–10.0)
Time since first relapsec [years], median (quartiles)8.4 (0.6–23.4)5.1 (1.5–15.1)
Any prior adjuvant chemotherapy, n (%)22 (56.4%)28 (73.7%)
Prior adjuvant taxane and/or anthracycline therapy, n (%)22 (56.4%)26 (68.4%)
Number of prior palliative endocrine therapies, n (%)
 110 (25.6%)13 (34.2%)
 211 (28.2%)10 (26.3%)
 31 (2.6%)0
  1. aMultiple answers per patient were possible. bDFI was defined as the time from first R0 resection until first local relapse or occurrence of distant metastases, whichever occurred first. cIncludes both local breast cancer recurrence and distant metastases. BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; DFI = disease-free interval